| GRFS or NBIX: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-05-15 16:46:04 |
Czytaj oryginał (ang.) |
| Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript |
Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wandeler - President Biopharma Conference Call Participants Charles Pitman - Barclays Alvaro Lenze - Alantra Equities Jaime Escribano - Banco Santander Guilherme Sampaio - CaixaBank Danny Segarra Hello, everyone. |
seekingalpha.com |
2025-05-12 20:51:03 |
Czytaj oryginał (ang.) |
| Grifols says on course to meet 2025 outlook as net profit triples |
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance. |
reuters.com |
2025-05-12 18:47:14 |
Czytaj oryginał (ang.) |
| IBL International collaborates with Grifols on advanced biomarker panels |
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols' random access, single molecule coun. |
businesswire.com |
2025-04-08 13:29:00 |
Czytaj oryginał (ang.) |
| Brookfield resumes Grifols takeover talks, El Confidencial reports |
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial reported on Wednesday, citing unidentified industry sources. |
reuters.com |
2025-04-02 07:03:50 |
Czytaj oryginał (ang.) |
| Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale |
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products. |
seekingalpha.com |
2025-02-27 14:58:12 |
Czytaj oryginał (ang.) |
| Grifols expects to boost revenue and free cash flow, shares soar |
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value. |
reuters.com |
2025-02-27 13:23:12 |
Czytaj oryginał (ang.) |
| Grifols' sales rise over 10% in 2024, above target |
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% sales growth. |
reuters.com |
2025-02-26 14:18:44 |
Czytaj oryginał (ang.) |
| Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. |
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-02-13 12:05:00 |
Czytaj oryginał (ang.) |
| Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition |
Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% |
globenewswire.com |
2025-02-06 08:07:00 |
Czytaj oryginał (ang.) |
| Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease |
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to identify plasma-based biomarkers that could indicate a person's likelihood of developing Parkinson's disease (PD) many years before clinical diagnosis. The initiative, called “Chronos-PD,” could accelerate the discovery of new diagnostic tools as well as the identification and development of novel disease-modifying therapeutics. |
globenewswire.com |
2025-01-14 08:00:00 |
Czytaj oryginał (ang.) |
| Mason Capital complains about Grifols' transparency to Spanish regulator |
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols. |
reuters.com |
2025-01-13 12:55:24 |
Czytaj oryginał (ang.) |
| Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols |
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the “CNMV”) calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the “Board”). In the letter, Mason urges the CNMV. |
businesswire.com |
2025-01-13 12:00:00 |
Czytaj oryginał (ang.) |
| Flat Footed Calls for Prompt Governance Overhaul at Grifols |
BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Footed”), holders of an aggregate 4.64% of the voting share capital of Grifols, S.A. (the “Grifols” or the “Company”). Flat Footed today sent a letter to the Grifols Board of Directors. The full text of the letter follows: Dear Mr. Glanzmann, Flat Footed LLC is the investment manager for FF Hybrid LP,. |
businesswire.com |
2024-12-10 14:23:00 |
Czytaj oryginał (ang.) |
| Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga |
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”) requesting the disclosure of important information regarding Tomas Daga, a nearly 25-year member of the Board and the Grifols family's closest advisor, so that Grifols shareholders have a better u. |
businesswire.com |
2024-12-04 04:30:00 |
Czytaj oryginał (ang.) |
| Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols |
MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B shares (including ADRs) in Grifols, S.A. (“Grifols” or the “Company”). As of 29 November 2024 closing prices, the Clients' aggregate stake in Grifols is valued at €275 million. The Clients thank the Transaction Committee for its wholehearted engagement with Brookfield and strongly support the decisi. |
businesswire.com |
2024-12-04 04:00:00 |
Czytaj oryginał (ang.) |
| Grifols: More Attractive Than In A Very Long Time |
I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher. |
seekingalpha.com |
2024-11-29 14:30:19 |
Czytaj oryginał (ang.) |
| Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday? |
On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition. |
benzinga.com |
2024-11-29 11:29:33 |
Czytaj oryginał (ang.) |
| Grifols Stock Declines After Brookfield Drops Buyout Offer |
Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation. |
zacks.com |
2024-11-28 13:06:12 |
Czytaj oryginał (ang.) |
| Grifols shares tumble after report on Brookfield abandoning takeover plan |
Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm. |
reuters.com |
2024-11-27 05:25:35 |
Czytaj oryginał (ang.) |
| Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% |
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential. |
zacks.com |
2024-11-20 12:31:39 |
Czytaj oryginał (ang.) |
| Grifols: Brookfields potential $6.8 bln offer undervalues the firm |
Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential. |
reuters.com |
2024-11-19 10:25:20 |
Czytaj oryginał (ang.) |
| Spanish court opens investigation into Gotham City's attack on Grifols |
An investigating magistrate at the Spanish High Court said on Tuesday it had opened an investigation into U.S.-based short seller Gotham City's actions that brought down the share price of Spanish pharmaceutical firm Grifols in January. |
reuters.com |
2024-11-19 07:54:31 |
Czytaj oryginał (ang.) |
| Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors |
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason reiterated the Company's corporate governance deficiencies, which have inflicted large losses on all shareholders and resulted in a rumored take-private by affiliates of Broo. |
businesswire.com |
2024-11-19 04:30:00 |
Czytaj oryginał (ang.) |
| Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says |
Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after finishing due diligence, news website El Confidencial reported on Monday, citing sources close to the matter. |
reuters.com |
2024-11-18 04:58:46 |
Czytaj oryginał (ang.) |
| Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors |
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason highlights numerous corporate governance failures that have resulted in Grifols' depressed share price and a rumored transaction with affiliates of Brookfield Asset Managemen. |
businesswire.com |
2024-11-08 17:54:00 |
Czytaj oryginał (ang.) |
| Grifols on track to meet 2024 targets despite third-quarter profit drop |
Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago. |
reuters.com |
2024-11-07 13:58:34 |
Czytaj oryginał (ang.) |
| Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down |
Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage. |
seekingalpha.com |
2024-10-03 21:20:55 |
Czytaj oryginał (ang.) |
| Grifols plans to invest $402 million in new industrial centre, El Economista says |
Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citing unidentified company sources. |
reuters.com |
2024-09-30 07:12:57 |
Czytaj oryginał (ang.) |
| Significant Shareholders Exercise Right to Grifols Board Seat |
BARCELONA, Spain--(BUSINESS WIRE)--Significant Grifols shareholders fill a vacant board seat, appointing pharma leader Paul Herendeen to drive value and improve governance. |
businesswire.com |
2024-09-19 19:23:00 |
Czytaj oryginał (ang.) |
| Grifols Egypt Collaborates with Orange Business to Deliver New Data Center and Communications Infrastructure, Supporting Advanced Medical Processes |
CAIRO--(BUSINESS WIRE)--Orange Business is pleased to announce the successful completion of the first phase of a new data center and communications infrastructure for Grifols Egypt for its Plasma Derivatives (GEPD) facility in the Medical City within the New Administrative Capital. The partnership involves delivering co-location services through the ACUD (Administrative Capital for Urban Development) commercial and telco data center. This includes communication services, support in equipment pr. |
businesswire.com |
2024-09-11 08:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. |
accesswire.com |
2024-09-06 15:00:00 |
Czytaj oryginał (ang.) |
| Grifols S.A. May Have Committed Fraud And Investors Are Urged To Contact The Schall Law Firm About An Inquiry |
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws. |
accesswire.com |
2024-09-05 15:00:00 |
Czytaj oryginał (ang.) |